



Nominations for Appointment to the Grants Working Group (GWG)

Appointment of New Members

Allan Robins, PhD

Allan Robins is currently an Independent Consultant in the area of cell therapy manufacturing, process development and manufacturing scale up. He was previously Senior Vice President, Science and Technology at ViaCyte from June 2012 until June 2017. Dr. Robins was Acting CEO of ViaCyte from May 2011 until June 2012 and Vice President and Chief Technology Officer from 2004 until 2011. He oversaw company-wide cell manufacturing and process development activities along with research operations in Athens, Georgia. Prior to ViaCyte, Dr. Robins served as Senior Vice President and Chief Scientific Officer of BresaGen, Inc., the United States subsidiary of BresaGen Limited, an Australian biotechnology company that has since been acquired by Hospira, Inc. Under Dr. Robins' leadership, BresaGen, Inc. was awarded significant support for its stem cell research from the National Institutes of Health. BresaGen merged with ViaCyte's predecessor companies in 2004. Prior to BresaGen, Inc., Dr. Robins was Vice President and Chief Scientific Officer of BresaGen Limited, where he helped raise over \$30 million and developed a proprietary expression system which continues to be used in the production of protein pharmaceuticals. Dr. Robins received a B.S. with honors in biochemistry and a Ph.D. in molecular biology from the University of Adelaide in Australia. He followed his studies with postdoctoral work at Cambridge University in England.